180 Life Sciences Corp. Logo

180 Life Sciences Corp.

ATNF

(1.2)
Stock Price

2,09 USD

-534.65% ROA

3043.52% ROE

-0.09x PER

Market Cap.

1.211.777,00 USD

-105.81% DER

0% Yield

-7559.37% NPM

180 Life Sciences Corp. Stock Analysis

180 Life Sciences Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

180 Life Sciences Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.28x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (9%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-538.84%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-2353.92%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

180 Life Sciences Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

180 Life Sciences Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

180 Life Sciences Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

180 Life Sciences Corp. Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

180 Life Sciences Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 1.074.283 100%
2019 2.035.319 47.22%
2020 2.293.004 11.24%
2021 3.948.305 41.92%
2022 2.432.565 -62.31%
2023 4.419.976 44.96%
2023 2.784.528 -58.73%
2024 2.487.952 -11.92%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

180 Life Sciences Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 343.884
2018 7.669.562 95.52%
2019 5.894.553 -30.11%
2020 3.316.277 -77.75%
2021 11.692.698 71.64%
2022 15.465.400 24.39%
2023 9.732.772 -58.9%
2023 10.692.972 8.98%
2024 4.899.000 -118.27%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

180 Life Sciences Corp. EBITDA
Year EBITDA Growth
2017 -343.884
2018 -8.720.769 96.06%
2019 -20.791.042 58.06%
2020 -5.522.779 -276.46%
2021 -15.531.055 64.44%
2022 -17.788.961 12.69%
2023 -14.021.976 -26.86%
2023 -13.371.824 -4.86%
2024 -7.291.040 -83.4%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

180 Life Sciences Corp. Gross Profit
Year Gross Profit Growth
2017 0
2018 0 0%
2019 -72.244 100%
2020 -125.333 42.36%
2021 -116.297 -7.77%
2022 -109.004 -6.69%
2023 0 0%
2023 -105.675 100%
2024 -95.924 -10.17%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

180 Life Sciences Corp. Net Profit
Year Net Profit Growth
2017 123.764
2018 -14.495.440 100.85%
2019 -25.394.046 42.92%
2020 -12.006.760 -111.5%
2021 -20.324.648 40.93%
2022 -38.726.259 47.52%
2023 -41.063.040 5.69%
2023 -19.935.112 -105.98%
2024 47.124 42403.52%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

180 Life Sciences Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 12
2018 -1.450 100.83%
2019 -876 -65.6%
2020 -255 -243.14%
2021 -248 -3.24%
2022 -387 36.18%
2023 -5 -7640%
2023 -53 90.38%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

180 Life Sciences Corp. Free Cashflow
Year Free Cashflow Growth
2017 -497.357
2018 -3.949.972 87.41%
2019 -3.463.056 -14.06%
2020 -3.871.961 10.56%
2021 -19.371.428 80.01%
2022 -12.127.585 -59.73%
2023 -10.922.223 -11.04%
2023 -1.775.475 -515.17%
2024 727.170 344.16%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

180 Life Sciences Corp. Operating Cashflow
Year Operating Cashflow Growth
2017 -497.357
2018 -3.919.145 87.31%
2019 -3.318.654 -18.09%
2020 -3.871.961 14.29%
2021 -19.371.428 80.01%
2022 -12.127.585 -59.73%
2023 -10.922.223 -11.04%
2023 -1.775.475 -515.17%
2024 727.170 344.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

180 Life Sciences Corp. Capital Expenditure
Year Capital Expenditure Growth
2017 0
2018 30.827 100%
2019 144.402 78.65%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

180 Life Sciences Corp. Equity
Year Equity Growth
2017 5.000.005
2018 -7.676.945 165.13%
2019 38.570.902 119.9%
2020 30.286.869 -27.35%
2021 39.322.695 22.98%
2022 11.343.918 -246.64%
2023 -149.327 7696.7%
2023 -127.733 -16.91%
2024 -417.987 69.44%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

180 Life Sciences Corp. Assets
Year Assets Growth
2017 117.058.354
2018 1.459.215 -7922.01%
2019 51.884.468 97.19%
2020 55.533.370 6.57%
2021 62.713.670 11.45%
2022 19.650.248 -219.15%
2023 4.958.085 -296.33%
2023 5.259.476 5.73%
2024 3.911.445 -34.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

180 Life Sciences Corp. Liabilities
Year Liabilities Growth
2017 4.233.131
2018 9.136.160 53.67%
2019 13.313.566 31.38%
2020 25.246.501 47.27%
2021 23.390.975 -7.93%
2022 8.306.330 -181.6%
2023 5.107.412 -62.63%
2023 5.387.209 5.19%
2024 4.329.432 -24.43%

180 Life Sciences Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.18
Net Income per Share
-13.65
Price to Earning Ratio
-0.09x
Price To Sales Ratio
7.3x
POCF Ratio
-0.26
PFCF Ratio
-0.29
Price to Book Ratio
-2.59
EV to Sales
3.06
EV Over EBITDA
-0.06
EV to Operating CashFlow
-0.12
EV to FreeCashFlow
-0.12
Earnings Yield
-11.57
FreeCashFlow Yield
-3.5
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
11.82
Graham NetNet
-3.46

Income Statement Metrics

Net Income per Share
-13.65
Income Quality
0.34
ROE
30.44
Return On Assets
-3.21
Return On Capital Employed
85.3
Net Income per EBT
0.84
EBT Per Ebit
1.67
Ebit per Revenue
-53.78
Effective Tax Rate
-0.16

Margins

Sales, General, & Administrative to Revenue
40.38
Research & Developement to Revenue
13.85
Stock Based Compensation to Revenue
8.63
Gross Profit Margin
0.38
Operating Profit Margin
-53.78
Pretax Profit Margin
-89.74
Net Profit Margin
-75.59

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-4.61
Free CashFlow per Share
-4.61
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-425.46
Return on Tangible Assets
-5.35
Days Sales Outstanding
21.89
Days Payables Outstanding
10356.21
Days of Inventory on Hand
0
Receivables Turnover
16.67
Payables Turnover
0.04
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,25
Book Value per Share
-0,45
Tangible Book Value per Share
-2.16
Shareholders Equity per Share
-0.45
Interest Debt per Share
0.54
Debt to Equity
-1.06
Debt to Assets
0.11
Net Debt to EBITDA
0.08
Current Ratio
0.58
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-104682
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.4
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.36

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

180 Life Sciences Corp. Dividends
Year Dividends Growth

180 Life Sciences Corp. Profile

About 180 Life Sciences Corp.

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

CEO
Mr. Lloyd Blair Jordan L.L.B.,
Employee
4
Address
Building 4
Palo Alto, 94306

180 Life Sciences Corp. Executives & BODs

180 Life Sciences Corp. Executives & BODs
# Name Age
1 Prof. Jagdeep Nanchahal M.D., Ph.D.
Co-Founder & Chairman of Clinical Advisory Board
70
2 Mr. Ozan Pamir C.F.A.
Chief Financial Officer & Secretary
70
3 Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Director
70
4 Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Interim Chief Executive Officer & Director
70
5 Sir Marc Feldmann Ph.D.
Co-Founder
70

180 Life Sciences Corp. Competitors